Cargando…

Early Onset Neutropenia due to Rituximab Therapy in Mantle Cell Lymphoma: A Case Report

Cases of late onset neutropenia (LON) after rituximab therapy have been documented, but few cases have been documented of early onset neutropenia (EON). We present a case report of a patient with mantle cell lymphoma who presented with EON, only 6 days after initiation of rituximab therapy, notable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nelson, Blessie Elizabeth, Tipton, Shelby, Venkatesan, Rohit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256914/ https://www.ncbi.nlm.nih.gov/pubmed/34267851 http://dx.doi.org/10.14740/jh814

Ejemplares similares

The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas
por: Tesfa, Daniel, et al.
Publicado: (2021)

Gastrointestinal Perforation after Rituximab Therapy in Mantle Cell Lymphoma: A Case Report
por: Adashek, Michael, et al.
Publicado: (2018)

An Advanced AIDS Patient With CD4 <20 and Plasmablastic Lymphoma Achieving Complete Response With the V-EPOCH Regimen
por: Nelson, Blessie, et al.
Publicado: (2020)

Standard-Dose Rituximab as Effective Therapy for Treating Malignancy-Related Hemophagocytic Lymphohistiocytosis in the Eldery: A Case Report
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2021)

Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia
por: Arroyo-Ávila, Mariangelí, et al.
Publicado: (2015)

Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome
por: Yamazaki, Mayuko, et al.
Publicado: (2019)

Late-onset neutropenia due to clozapine
por: Tatar, Zeynep Baran, et al.
Publicado: (2015)

CD5+ Diffuse Large B-Cell Lymphoma With Leukemic Transformation: A Rare Case With Central Nervous System Involvement, Treated With R-CHOP and Intrathecal Methotrexate/Cytarabine
por: Cordova, Justin, et al.
Publicado: (2021)

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
por: Borgerding, Andrea, et al.
Publicado: (2009)

Leuconostoc sp. Meningitis in a Patient Treated with Rituximab for Mantle Cell Lymphoma
por: Holik, Hrvoje, et al.
Publicado: (2015)

Bendamustine/rituximab: Neutropenia, fever and inflammation: case report
Publicado: (2022)

Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP
por: Choi, Yong Won, et al.
Publicado: (2014)

Cancer screenings during the COVID-19 pandemic: An analysis of public interest trends
por: Greiner, Benjamin, et al.
Publicado: (2022)

Chylous Ascites due to Mantle Cell Lymphoma
por: Fernandes, Ricardo, et al.
Publicado: (2018)

Peritonitis due to colon mantle cell lymphoma
por: Villavicencio, Rafael, et al.
Publicado: (2021)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
por: Darwish, Mona, et al.
Publicado: (2014)

Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab
por: Marcacci, Gianpaolo, et al.
Publicado: (2021)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Rituximab-Related Late-Onset Neutropenia in Patients with Rheumatic Diseases: Successful Re-Challenge of the Treatment
por: Reitblat, Tatiana, et al.
Publicado: (2015)

A case of late-onset neutropenia secondary to rituximab in a patient with mucous membrane pemphigoid
por: Schultz, Brittney, et al.
Publicado: (2019)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study
por: Shimizu, Yuki, et al.
Publicado: (2023)

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
por: Yamshon, Samuel, et al.
Publicado: (2023)

Case of HER2neu+ Invasive Pleomorphic Lobular Carcinoma With Response to Conventional Neoadjuvant Chemotherapy: A Viable Option for an Exceedingly Rare Breast Cancer Type
por: Nelson, Blessie, et al.
Publicado: (2020)

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
por: Salmon, J H, et al.
Publicado: (2015)

Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020)

P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY
por: Tivey, A., et al.
Publicado: (2022)

Sarcoid-Like Reaction in the Kidney Following Rituximab for Mantle Lymphoma in a 60-Year-Old Man
por: Mrabet, Sanda, et al.
Publicado: (2023)

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
por: Fischer, Luca, et al.
Publicado: (2023)

Mantle Cell Lymphoma Case Report
por: Podzolkov, V.I., et al.
Publicado: (2018)

Novel targeted therapies for mantle cell lymphoma
por: Alinari, Lapo, et al.
Publicado: (2012)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2022)

P1089: ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA
por: Qu, Chang-Ju, et al.
Publicado: (2023)

Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab
por: Ajeganova, Sofia, et al.
Publicado: (2017)

Spontaneous Splenic Rupture and Rituximab-Induced Acute Thrombocytopenia in a Patient with High-Risk Mantle Cell Lymphoma
por: Williams, Jared, et al.
Publicado: (2019)

A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
por: Nakamura, Nobuhiko, et al.
Publicado: (2022)

Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report
por: Higer, Maximilian, et al.
Publicado: (2020)

Improvement of the rituximab–induced cell death by potentiation of the store-operated calcium entry in mantle cell lymphoma cell lines
por: Doignon, Isabelle, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s8huslsvt1qgps8uh1iuanl470